AstraZeneca to buy Gracell Technologies for $1.2bn
GRACELL SP ADR-A
$10.25
19:30 15/07/24
0.00%
$0.00
AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.
AstraZeneca
10,416.00p
13:55 23/12/24
1.56%
160.00p
FTSE 100
8,095.80
13:55 23/12/24
n/a
n/a
FTSE 350
4,467.35
13:55 23/12/24
n/a
n/a
FTSE All-Share
4,425.06
13:55 23/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,012.33
13:55 23/12/24
1.27%
251.21
Under the terms of the deal, AstraZeneca will acquire all of Gracell’s shares at $2 per share in cash, plus a non-tradable contingent value right of $0.30 per ordinary share payable upon achievement of a specified regulatory milestone.
The upfront cash portion represents a 62% premium to Gracell’s closing market price on December 22, 2023.
Reporting by Frank Prenesti for Sharecast.com